Next Article in Journal
A Role for Neuropeptide S in Alcohol and Cocaine Seeking
Next Article in Special Issue
Synthesis of Quinolones and Zwitterionic Quinolonate Derivatives with Broad-Spectrum Antibiotic Activity
Previous Article in Journal
Inhibition of NLRP3 by Fermented Quercetin Decreases Resistin-Induced Chemoresistance to 5-Fluorouracil in Human Colorectal Cancer Cells
Previous Article in Special Issue
Antioxidant and Antibacterial Activity of Helichrysum italicum (Roth) G. Don. from Central Europe
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 7
10.3390/ph15070799
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors

by
Fawzia Faleh Albelwi
1,
Hanaa M. Abdu Mansour
1,
Maram M. Elshatanofy
2,
Yeldez El Kilany
2,
Kamal Kandeel
3,
Bassma H. Elwakil
4,
Mohamed Hagar
2,
Mohamed Reda Aouad
1,
El Sayed H. El Ashry
2,
Nadjet Rezki
1,* and
Maged A. El Sawy
5
1
Department of Chemistry, Faculty of Science, Taibah University, Al-Madinah Al-Munawarah 30002, Saudi Arabia
2
Department of Chemistry, Faculty of Science, Alexandria University, Alexandria 21321, Egypt
3
Department of Biochemistry, Faculty of Science, Alexandria University, Moharam Beik, Alexandria 21547, Egypt
4
Department of Medical Laboratory Technology, Faculty of Applied Health Sciences Technology, Pharos University in Alexandria, Alexandria 21311, Egypt
5
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University, Alexandria 21311, Egypt
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(7), 799; https://0-doi-org.brum.beds.ac.uk/10.3390/ph15070799
Submission received: 24 April 2022 / Revised: 3 June 2022 / Accepted: 5 June 2022 / Published: 27 June 2022
(This article belongs to the Special Issue Novel Antibacterial Agents 2022)
Browse Figures
Versions Notes

Abstract

:
New medications are desperately needed to combat rising drug resistance among tuberculosis (TB) patients. New agents should ideally work through unique targets to avoid being hampered by preexisting clinical resistance to existing treatments. The enoyl-acyl carrier protein reductase InhA of M. tuberculosis is one of the most crucial targets since it is a promising target that has undergone extensive research for anti-tuberculosis drug development. A well-known scaffold for a variety of biological activities, including antitubercular activity, is the molecular linkage of a1,2,3-triazole with an acetamide group. As a result, in the current study, which was aided by ligand-based molecular modeling investigations, 1,2,3-triazolesweredesigned and synthesized adopting the CuAAC aided cycloaddition of 1-(4-(prop-2-yn-1-yloxy)phenyl)ethanone with appropriate acetamide azides. Standard spectroscopic methods were used to characterize the newly synthesized compounds. In vitro testing of the proposed compounds against the InhA enzyme was performed. All the synthesized inhibitors completely inhibited the InhA enzyme at a concentration of 10 µM that exceeded Rifampicin in terms of activity. Compounds 9, 10, and 14 were the most promising InhA inhibitors, with IC50 values of 0.005, 0.008, and 0.002 µM, respectively. To promote antitubercular action and investigate the binding manner of the screened compounds with the target InhA enzyme’s binding site, a molecular docking study was conducted.

1. Introduction

Triazoles, a class of nitrogen-containing heterocycle, are well known as intriguing structural motifs with fascinating applications in many areas of disciplines such as materials research, synthetic organic chemistry, and drug discovery [1].
Due to their well-documented therapeutic potential, 1,2,3-triazole analogues are attractive target substances for researchers worldwide. They are important antiviral [2,3], antibacterial [4,5,6,7], antifungal [8,9], antimalarial [10,11], anticancer [12,13,14,15,16,17,18], analgesic [11], antihypertensive [12], anticonvulsant [19], and CNS depressing [20] agents.
Furthermore, as enticing linker units suitable for connecting two pharmacophores in order to develop novel polyfunctional drugs, 1,2,3-triazoles have become increasingly relevant and important in the generation of bioactive and multifunctional drugs [21]. Due to the obvious polarity of the core of 1,2,3-triazoles, they induce non-covalent bonding interactions with microbial proteins, such as dipole–dipole and pi-stacking, which restricts their development, resulting in a potent antibacterial drug [22,23].
Moreover, several drugs on the market, such as rufinamide (anticonvulsant), cetirizine (antibiotic), and tazobactam (antibacterial agent) have inserted a 1,2,3 triazole core into their framework [24] (Figure 1).
In the literature, there are numerous 1,2,3-triazoles tethered to bioactive heterocyclic moieties, such as (Figure 2A–D), that have been documented as promising antitubercular agents [25,26,27,28,29,30,31]. In particular, the 1,4-disubstituted 1,2,3-triazole derivatives were identified and proven to have high efficacy against Mycobacterium tuberculosis. For instance, lead structure A with MIC = 5.8 μg/mL was constructed from a triazole scaffold substituted at 1-position by a 4-bromobenzyl moiety and at 4-position by a 4-chlorophenoxymethyl moiety [32] (Figure 3). The importance of the phenoxy methyl moiety in the development of the new candidate with significant antimycobacterium activity is represented by the lead structure (Figure 3B), which exerts its activity through inhibition of the enoyl-acyl carrier protein reductase InhA enzyme, IC50 = 0.38 μM [33].
On the other hand, different aryl derivatives can be linked to the 1,2,3-triazole scaffold via an acetamide linker, as shown by lead structures (Figure 3C,D), which have MICs of 6.25 and 0.08 g/mL, respectively, and have shown good antitubercular activity [34,35].
In light of these facts, and as a follow-up to our efforts on the synthesis of such bioactive scaffolds [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18], we have anticipated to design and synthesize a novel 1,4-disubstituted 1,2,3-triazolecontainingacetamide in order to link aryl derivatives to the triazole motif and an acetyl phenoxy methyl moiety substituting the 4-position of the triazole ring. The resulting 1,2,3-triazole adducts were investigated as inhibitors of the NADH-dependent enoyl-acyl carrier protein reductase enzyme. InhA contributes to the manufacture of key components of the mycobacterial cell walls through involvement in the type II fatty acid biosynthetic pathway. Among the studied compounds, one demonstrated good inhibitory activity against the InhA enzyme with an IC50 of 0.002 μM and was considered the most active molecule. Molecular modeling was also used to evaluate the pattern of binding of the tested drugs to the target enzyme.

2. Results and Discussion

2.1. Chemistry

The propargylation of 4-hydroxyacetophenone (1) with 3-bromoprop-1-yne has been carried out in dimethylformamide as a solvent and in the presence of a catalytic amount of potassium carbonate as the basic catalyst, which resulted in the formation of precursor 1-(4-(prop-2-yn-1-yloxy) phenyl)4thenone (2) in 91% yield, Scheme 1.
The formation of O-propargylated acetophenone 2 as the key intermediate has been inferred from its spectral information (IR, 1H NMR and 13C NMR).
The IR spectrum unveiled a significant characteristic absorption bands, confirming the proposed structure. Sharp bands at 2100 and 3210 cm−1 were detected, which were ascribed to the acetylenic hydrogen carbons (C≡C) and (≡C-H) groups, respectively. In addition, the vanishing of the hydroxyl absorption band proved that it had been propargylated.
Examination of 1H and 13C NMR spectra of alkyne showed the existence of an alkyne side chain; based on the presence of a diagnostic doublet at δH 4.77 ppm attributed to OCH2 protons. The ≡C-H proton resonated as a broad singlet at δH 2.57 ppm overlapping with the signal containing three protons of the methyl group. The aromatic protons resonated in the aromatic area as expected (δH 7.03–7.97 ppm).
In contrast, the existence of significant propargyl carbon signals (OCH2 and C≡C) at δC 51.08, 71.48 and 73.00 ppm was also compatible with such acetylenic side chains. The signals recorded at δC 109.68–156.51 ppm were assigned to the aromatic carbons of the phenyl ring. The carbonyl carbon was also observed in the downfield area at δC 192.09 ppm.
The O-propargylated acetophenone 2 is a versatile key intermediate for the click synthesis of novel 1,2,3-triazoles-based acetophenone 9–14. Thus, 1,3-dipolar cycloaddition of the synthesized alkyne 2 with some appropriate phenyl 3–5 and/or benzyl acetamide azides 6–8 afforded the corresponding 1,4-disubstituted 1,2,3-triazoles 9–14 in very good yields (87–90%), Scheme 1. The click reactions were carried out at room temperature for 6–8 h in the presence of a mixture of dimethylsulfoxide and water (DMSO/H2O; 1:1) as solvents and catalytic amount of copper sulfate and Na ascorbate as catalysts as described in Scheme 1.
The combination of IR, 1H NMR, and 13C NMR spectral analysis has verified the formation of triazoles 9–14. Compound 9 has been used as a model in order to assign, absorption bands in the IR spectra and resonance peaks in the NMR spectra.
Triazole 9 has an IR spectrum that matches its assigned structure. The disappearance of the peaks belonging to C≡C and ≡C-H absorption bands and the appearance of a sharp absorption at 3300 cm−1 attributed to the NH group of the acetamide linkage indicates in part that the cycloaddition reaction has taken place.
The 1H NMR spectrum of triazole 9 reveals the disappearance of the signal attributed to the ≡C-H proton of its precursor O-alkyne 2 and the appearance of a diagnostic singlet at δH 8.25 ppm, assigned to the CH-1,2,3-triazole proton. The spectrum also shows two pairs of singlets for the OCH2 and NCH2 protons at δH5.24 and 5.41 ppm, respectively. Moreover, the assigned CONH proton at δH 10.29 ppm was also in agreement with the assigned 1,2,3-triazole 9. Further assignment of the aromatic protons revealed that they were resonated at their appropriate positions and listed in the experimental section.
In addition, the 13C NMR spectrum of compound 9 also revealed the absence of the two sp-carbons and the presence of OCH2 and NCH2-carbons at δC 52.96 and δC 61.74 ppm, respectively. A new signal also appeared at δC165.23 assigned to the carbonyl amide carbon (CONH). All sp2 carbons were observed in the aromatic region (See experimental section).
On the other hand, the click synthesis has also been evidenced by the 19F NMR spectrum of compound 9, which showed multiple signals recorded between δF −124.75 to −124.69 ppm, which confirmed the presence of an aromatic fluorine atom in the structure.

2.2. Biological Evaluation

A brief screening of the synthesized compounds was tested as a direct InhA enzyme inhibitor. The InhA inhibition (IC50) was calculated (Table 1). All synthesized inhibitors completely inhibited the InhA enzyme at a concentration of 10 µM (Figure 4), excelling in terms of activity, with a rifampicin IC50 of value 8.5 µM. Moreover, all synthesized inhibitors showed activity better than isoniazid IC50 of value 0.054 µM except compound 13 IC50 of value 0.084 µM [36]. Furthermore, 9,10, and 14 were the most promising InhA inhibitors, with IC50 values of 0.005, 0.008, and 0.002 µM, respectively.

3. Molecular Modeling

Docking Simulations

All synthesized compounds are subjected to molecular docking studies into the binding site of inhA in order to understand hypothesized intermolecular interactions and consider the potential binding pattern that supports these drugs’ inhibitory effects. Molecular operating environment software was used to accomplish this (MOE 2016.0802). The protein data bank provided the X-ray crystal structures of InhA (PDB ID: 4UVD) with its co-crystallized ligand (HRW) (PDB DOI: 10.2210/pdb4UVG/pdb).
The docking poses were chosen based on the top-scored conformation with the best binding interactions found by the MOE search algorithm and scoring function. Furthermore, binding energy scores, creation of binding interactions with neighboring amino acid residues, and relative placement of docked poses in respect to co-crystallized ligands all played a role in defining binding affinities to the enzyme binding pockets and docking to the InhA active site.
The most active compounds, 9, 10, and 14, were found to be at the best-docked position in the active site of the inhA enzyme (4UVD), with binding energy scores (S) of −8.63, −8.97, and −9. kcal/mol and RMSDs of 1.78, 1.85, and 1.91, respectively. With key amino acids inside the pocket, these compounds can create a non-covalent bonding interaction. For instance, the compound 9 triazole ring forms a hydrophobic bond of 3.86 Å with Met98. Similarly, the compound 10 triazole ring forms a hydrogen bond of 3.25 Å with Met98. Along the same track, the compound 14 4-methoxy benzyl ring can interact via a hydrophobic bond of 4.59 Å with met98. Moreover, Met103 forms hydrogen bonds of 4.15 Å and 3.83 Å with compound 9 triazole ring and acetamide nitrogen of compound 14, respectively. Furthermore, Met161 shares hydrogen bonds of 4.35 and 3.88 Å with acetamide linker of compounds 10 and 14, respectively. Figure 5A,B, Figure 6A,B and Figure 7A,B. Accordingly, the importance of triazole scaffold and acetamide linker in future design of InhA inhibitors cannot be neglected. Compounds 11,12, and 13, on the other hand, which exhibit less invitro activity, showed main interactions with Met98. For example, the acetamide oxygen of compounds 11 and 12 forms hydrogen bonds of 3.12 Å, whereas compound 13, triazole ring, forms a hydrophobic interaction of 4.09 Å with Met98. There were no interactions between compounds 11, 12, and 13 and Met 103 and Met 161, which may explain why these compounds had lower in vitro activity (Figure 7A,B, Figure 8A,B, Figure 9A,B and Figure 10A,B). The reported InhA-Inhibitors Lead structure B IC50 = 0.38 μM was selected to dock into the 4UVD active site. Lead structure B showed (S) −7.39 kcal/mol and (RMSD) of 1.05 can occupy the active site of the enzyme through a hydrogen bond of 3.04 Å between 2-hydroxygroup and Met98 (Figure 11).

4. Experimental Methods

4.1. Chemistry

4.1.1. General Information

All reagents and solvents used were of the highest quality of analytical reagent grade and were used without further purification. Melting points were measured on a Stuart Scientific SMP1 and are uncorrected. TLC was performed on UV fluorescent Silica gel Merck 60 F254 plates, and the spots were visualized using a UV lamp (254 nm). SHIMADZU FTIR-Affinity-1S spectrometer was used for identification of functional groups in the range of 400–4000 cm−1. The NMR spectra were run with Bruker spectrometers (500 and 400 MHz) in the presence of TMS as internal reference. All azides used in this study were prepared according to reported procedures [37,38,39,40]

4.1.2. Synthesis Andof 1-(4-(Prop-2-Yn-1-yloxy) phenyl) ethan-1-one (2)

A mixture of 4-hydroxyacetophenone (1) (10 mmol) in dimethylformamide (10 mL) and potassium carbonate (12 mmol) was stirred for 1 h. Then, propargyl bromide (1.2 mmol) was added, and the stirring was continued for 4 h at 80 °C until the consumption of the starting material as indicated by TLC (hexane-ethyl acetate). After cooling, the mixture was poured onto crushed ice water and the precipitate formed was filtered, washed with water, dried and crystallized from ethanol to give the targeted O-propargylated acetophenone 2 as pale yellow powder in 91% yield, mp: 150–151 °C IR (υ, cm−1): 1250 (C-O), 1600 (C=C), 1680 (C=O), 2100 (C≡C), 2900 (CH-Al), 3070 (CH-Ar), 3210 (≡CH). 1H NMR (400 MHz, CDCl3) δH = 2.57 (bs, 4H, CH3 and ≡CH), 4.77 (d, 2H, J = 4.0 Hz, OCH2), 7.03 (d, 2H, J = 4.0 Hz, Ar-H), 7.97 (d, 2H, J = 12.0 Hz, Ar-H). 13C NMR (100 MHz, CDCl3): δC= 21.70 (CH3); 51.08 (OCH2); 71.48 (C≡CH); 73.00 (C≡CH); 109.68, 109.80, 125.21, 125.50, 125.80, 125.95, 126.23, 156.51, 156.51 (Ar-C); 192.23 (C=O) Figures S1–S3.

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(2-fluorophenyl)acetamide (9)

This compound was obtained as pale yellow solid in 87% yield, mp: 179–180 °C. IR (υ, cm−1): 1550 (C=C), 1670 (C=O), 1705 (C=O), 3060 (CH-Ar), 3300 (NH). 1H NMR (500 MHz, DMSO-d6): δH = 2.48 (s, 3H, CH3 overlapped with DMSO-d6), 5.24 (s, 2H, OCH2), 5.41 (s, 2H, NCH2), 7.13–7.25 (m, 5H, Ar-H), 7.86–7.89 (m, 1H, Ar-H), 7.91 (d, 2H, J =10 Hz, Ar-H), 8.25 (s, 1H, CH-1,2,3-triazole), 10.29 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): δC = 27.16 (CH3); 52.96 (OCH2); 61.74 (NCH2); 115.34, 115.89, 116.40, 124.16, 124.97, 125.96, 126.08, 126.19, 126.32, 127.12, 130.84, 142.49, 162.40, 165.23 (Ar-C, CONH); 196.89 (C=O). 19F NMR (377 MHz, DMSO-d6): δF = −124.75 to −124.69 (m, 1F, Ar-F) Figures S4–S7.

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(4-nitrophenyl)acetamide (10)

This compound was obtained as white solid in 89% yield, mp: 185–186 °C. IR (υ, cm−1): 1580 (C=C), 1680 (C=O), 1710 (C=O), 3030 (Ar CH), 3325 (NH). 1H NMR (400 MHz, DMSO-d6): δH = 2.48 (s, 3H, CH3 overlapped with DMSO-d6), 5.19 (s, 2H, OCH2), 5.74 (s, 2H, NCH2), 7.01–7.08 (m, 2H, Ar-H), 7.18–7.28 (m, 4H, Ar-H), 7.73–7.77 (m, 2H, Ar-H), 8.38 (s, 1H, CH-1,2,3-triazole), 9.82 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δC = 27.31 (CH3); 52.37 (OCH2); 61.95 (NCH2); 115.21, 115.71, 129.16, 129.74, 130.26, 132.38, 133.49, 133.83, 148.91, 158.63, 161.96, 163.33 (Ar-C, CONH); 192.06 (C=O).

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(3,4-dichlorophenyl)acetamide (11)

This compound was obtained as pale yellow solid in 89% yield, mp: 205–206 °C. IR (υ, cm−1): 1540 (C=C), 1670 (C=O), 1705 (C=O), 3090 (CH-Ar), 3325 (NH). 1H NMR (400 MHz, DMSO-d6): δH = 2.54 (s, 3H, CH3 overlapped with DMSO-d6), 5.28 (s, 2H, OCH2), 5.38 (s, 2H, NCH2), 7.17 (d, 2H, J = 8.0 Hz, Ar-H), 7.45–7.60 (m, 2H, Ar-H), 7.93–7.95 (m, 3H, Ar-H), 8.30 (s, 1H, CH-1,2,3-triazole), 10.85 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δC = 26.88 (CH3); 52.62 (OCH2); 61.70 (NCH2); 114.98, 119.79, 120.96, 125.89, 127.21, 130.52, 130.90, 130.98, 131, 17, 131.36, 131.63, 138.80, 142.65, 162.30, 165.25 (Ar-C, CONH); 197.09 (C=O) Figures S8–S10.

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(4-fluorobenzyl)acetamide (12)

This compound was obtained as pale yellow solid in 88% yield, mp: 165–166 °C. IR (υ, cm−1): 1540 (C=C), 1670 (C=O), 1695 (C=O), 3070 (CH-Ar), 3290 (NH). 1H NMR (400 MHz, DMSO-d6): δH = 2.51 (s, 3H, CH3 overlapped with DMSO-d6), 4.30 (d, 2H, J = 8.0 Hz, NHCH2), 5.19 (s, 2H, OCH2), 5.25 (s, 2H, NCH2), 7.15–7.16 (m, 4H, Ar-H), 7.30–7.33 (m, 2H, Ar-H), 7.94 (d, 2H, J = 8.0 Hz, Ar-H), 8.25 (s, 1H, CH-1,2,3-triazole), 8.89 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δC = 26.88 (CH3); 42.35 (NHCH2); 52.05 (OCH2); 61.71 (NCH2); 114.97, 115.46, 115.67, 127.02, 129.74, 129.80, 130.51, 130.97, 135.31, 160.48, 162.31, 162.93, 165.93 (Ar-C, CONH); 197.07 (C=O). 19F NMR (172 MHz, DMSO-d6): δF = −118.56 to −118.48 (m, 1F, Ar-F) Figures S11–S14.

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(4-methylbenzyl)acetamide (13)

This compound was obtained as pale yellow solid in 89% yield, mp: 180–182 °C. IR (υ, cm−1): 1575 (C=C), 1670 (C=O), 1695 (C=O), 3040 (CH-Ar), 3295 (NH). 1H NMR (500 MHz, DMSO-d6): δH = 2.23 (s, 3H, CH3), 2.43 (s, 3H, COCH3 overlapped with DMSO-d6),4.24 (d, 2H, J = 5 Hz, NHCH2), 5.14 (s, 2H, OCH2), 5.23 (s, 2H, NCH2), 7.09–7.13 (m, 6H, Ar-H), 7.91 (d, 2H, J = 5 Hz, Ar-H), 8.20 (s, 1H, CH-1,2,3-triazole), 8.77 (t, 1H, J = 5 Hz, NH). 13C NMR (125 MHz, DMSO-d6): δC = 21.19 (CH3), 26.96 (COCH3); 40.38 (NHCH2); 52.15 (OCH2); 61.78 (NCH2); 115.05, 126.94, 127.93, 129.43, 129.45, 130.63, 131.00, 136.17, 136.64, 142.44, 162.41, 165.82 (Ar-C, CONH); 196.85 (C=O) Figures S15–S17.

2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol-1-Yl)-N-(4-methoxybenzyl)acetamide (14)

This compound was obtained as pale yellow solid in 90% yield, mp: 125–126 °C. IR (υ, cm−1): 1580 (C=C), 1680 (C=O), 1700 (C=O), 3070 (CH-Ar), 3350 (NH). 1H NMR (400 MHz, DMSO-d6): δH = 2.46 (s, 1H, CH3 overlapped with DMSO-d6), 3.69 (s, 3H, OCH3), 4.21 (d, 2H, J = 4.0 Hz, NHCH2), 5.13 (s, 2H, OCH2), 5.23 (s, 2H, NCH2), 6.86 (d, 2H, J = 4.0 Hz, Ar-H), 7.13 (d, 2H, J = 8.0 Hz, Ar-H), 7.18 (d, 2H, J = 8.0 Hz, Ar-H), 7.91 (d, 2H, J = 8.0 Hz, Ar-H), 8.20 (s, 1H, CH-1,2,3-triazole), 8.75 (t, 1H, J= 4.0 Hz, NH). 13C NMR (100 MHz, DMSO-d6): δC = 26.96 (COCH3); 42.39 (NHCH2); 52.15 (OCH2); 55.60 (OCH3); 61.78 (NCH2); 114.29, 115.05, 129.34, 130.63, 131.00, 131.13, 158.91, 162.41, 165.74 (Ar-C, CONH); 196.86 (C=O) Figures S18–S20.

4.2. Enzymatic Inhibition Experiments

M. tuberculosis InhA was overexpressed in E. coli while NADH was obtained from Sigma-Aldrich. The concentration of the pool INH–NAD was determined on the basis of ε330 equaled 6900 M−1 cm−1. The substrate 2-trans-decenoyl-CoA concentration was determined on the basis of ε260 equaled 22,600 M−1 cm−1.
For the inhibition assays with InhA, the pre-incubation reactions were performed in 80 μL (total volume) of 30 mM PIPES buffer solution, 150 mM NaCl, pH 6.8 at 25 °C containing 70 nM InhA and the tested compounds (at different concentrations). DMSO was used as co-solvent and its final concentration was 0.5%. After 2 h of pre-incubation, the addition of 35 μM substrate (trans-2-decenoyl-CoA) and 200 μM cofactor (NADH) initiated the reaction which was measured at 25 °C and at 340 nm (oxidation of NADH) using a spectrophotometer (PG-T80, PG Instruments lmited woodway lane, Leicester, UK). Control reactions were done under the same conditions but without the ligands. The pool of INH–NAD adducts was used as a positive control. The initial rates of the reactions were calculated. Rifampicin was used as a reference commercially known drug. The inhibition percentage of each compound was measured at 10 µM and the compounds’ inhibitory activity was expressed as the IC50 inhibition of InhA activity with respect to the control experiments [41].

4.3. Docking Study

Computer-aided docking experiments were performed using Molecular Operating Environment (MOE 2014.0802) software (Chemical Computing Group, Montreal, QC, Canada).

4.3.1. Preparation of the Protein Crystal Structures

The protein data bank provided the X-ray crystal structures of InhA (PDB ID: 4UVD) with its co-crystallized ligand (HRW). Explicit hydrogen atoms were added to the receptor complex structure and partial charges were calculated. The preparation was completed with structure preparation module employing protonated 3D function.
The co-crystal ligand (HRW) was extracted from their corresponding proteins and used as reference molecules for the validation study.

4.3.2. Preparation of the Selected Compounds for Docking

The target compounds were constructed using the builder module of MOE. The compounds were then collected in a database and prepared by adding hydrogens, calculating partial charges and energy minimizing using Force field MMFF94x.
The top-scored conformation with the best binding interactions detected by the MOE search algorithm and scoring function was the basis for the selection of the docking poses. In addition, binding energy scores, formation of binding interaction with the neighboring amino acid residues, and the relative positioning of the docked poses in comparison to the co-crystallized ligands were the factors determining the binding affinities to the binding pockets of the enzyme.

5. Conclusions

To target M. tuberculosis’ enoyl-acyl carrier protein reductase, the CuAAC of 1-(4-(prop-2-yn-1-yloxy) phenyl) ethanone with suitable acetamide azides was employed to develop and synthesize the 1,2,3-triazole molecular series. At a dose of 10 µM, all of the synthetic inhibitors completely inhibited the InhA enzyme and outperformed rifampicin in terms of activity. The most promising InhA inhibitors were 9,10, and 14, which had IC50 values of 0.005, 0.008, and 0.002 µM, respectively. As a result, our compounds may open the path for new, extremely effective anti-TB drugs.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/ph15070799/s1, Figure S1: IR spectrum of compound 2, Figure S2: 1H NMR spectrum of compound 2, Figure S3: 13C NMR spectrum of compound 2, Figure S4: IR spectrum of compound 9, Figure S5: 1H NMR spectrum of compound 9, Figure S6: 13C NMR spectrum of compound 9, Figure S7: 19F NMR spectrum of compound 9, Figure S8: IR spectrum of compound 11, Figure S9: 1H NMR spectrum of compound 11, Figure S10: 13C NMR spectrum of compound 11, Figure S11: IR spectrum of compound 12, Figure S12: 1H NMR spectrum of compound 12, Figure S13: 13C NMR spectrum of compound 12, Figure S14: 19F NMR spectrum of compound 12, Figure S15: IR spectrum of compound 13, Figure S16: 1H NMR spectrum of compound 13, Figure S17: 13C NMR spectrum of compound 13, Figure S18: IR spectrum of compound 14, Figure S19: 1H NMR spectrum of compound 14, Figure S20: 13C NMR spectrum of compound 14.

Author Contributions

Conceptualization, N.R.; Data curation, F.F.A., H.M.A.M., M.M.E., B.H.E., M.H., M.R.A., E.S.H.E.A., N.R. and M.A.E.S.; Formal analysis, Y.E.K., B.H.E. and N.R.; Funding acquisition, F.F.A. and N.R.; Investigation, M.M.E., M.R.A. and E.S.H.E.A.; Methodology, F.F.A., H.M.A.M., M.M.E., B.H.E., M.R.A., N.R. and M.A.E.S.; Project administration, K.K.; Supervision, Y.E.K. and K.K.; Writing—original draft, M.M.E., M.H., M.R.A., N.R. and M.A.E.S.; Writing—review & editing, M.H., M.R.A., N.R. and M.A.E.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and supplementary files.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Juríček, M.; Kouwer, P.H.; Rowan, A.E. Triazole: A unique building block for the construction of functional materials. Chem. Commun. 2011, 47, 8740–8749. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Jordão, A.K.; Ferreira, V.F.; Souza, T.M.; de Souza Faria, G.G.; Machado, V.; Abrantes, J.L.; de Souza, M.C.; Cunha, A. Synthesis and anti-HSV-1 activity of new 1, 2, 3-triazole derivatives. Bioorganic Med. Chem. 2011, 19, 1860–1865. [Google Scholar] [CrossRef] [Green Version]
  3. Pereira, D.; Fernandes, P. Synthesis and antibacterial activity of novel 4-aryl-[1, 2, 3]-triazole containing macrolides. Bioorganic Med. Chem. Lett. 2011, 21, 510–513. [Google Scholar] [CrossRef] [PubMed]
  4. Jiang, Z.; Gu, J.; Wang, C.; Wang, S.; Liu, N.; Jiang, Y.; Dong, G.; Wang, Y.; Liu, Y.; Yao, J. Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1, 2, 3-triazole-piperdine side chains. Eur. J. Med. Chem. 2014, 82, 490–497. [Google Scholar] [CrossRef] [PubMed]
  5. Feng, L.S.; Zheng, M.J.; Zhao, F.; Liu, D. 1, 2, 3-Triazole hybrids with anti-HIV-1 activity. Arch. Der Pharm. 2021, 354, 2000163. [Google Scholar] [CrossRef]
  6. Al-Blewi, F.F.; Almehmadi, M.A.; Aouad, M.R.; Bardaweel, S.K.; Sahu, P.K.; Messali, M.; Rezki, N.; El Ashry, E.S.H. Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1, 2, 3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents. Chem. Central J. 2018, 12, 1–14. [Google Scholar] [CrossRef]
  7. El Ashry, E.; Elshatanofy, M.; Badawy, M.; Kandeel, K.; Elhady, O.; Abdel-Sayed, M. Synthesis and Evaluation of Antioxidant, Antibacterial, and Target Protein-Molecular Docking of Novel 5-Phenyl-2, 4-dihydro-3H-1, 2, 4-triazole Derivatives Hybridized with 1, 2, 3-Triazole via the Flexible SCH2-Bonding. Russ. J. Gen. Chem. 2020, 90, 2419–2434. [Google Scholar] [CrossRef]
  8. Lopes, F.V.; Stroppa, P.H.F.; Marinho, J.A.; Soares, R.R.; de Azevedo Alves, L.; Goliatt, P.V.Z.C.; Abramo, C.; da Silva, A.D. 1, 2, 3-Triazole derivatives: Synthesis, docking, cytotoxicity analysis and in vivo antimalarial activity. Chem. Interact. 2021, 350, 109688. [Google Scholar] [CrossRef]
  9. Junqueira, G.G.; Carvalho, M.R.; de Andrade, P.; Lopes, C.D.; Carneiro, Z.A.; Sesti-Costa, R.; Silva, J.S.; Carvalho, I. Synthesis and in vitro evaluation of novel galactosyl-triazolo-benzenesulfonamides against Trypanosoma cruzi. J. Braz. Chem. Soc. 2014, 25, 1872–1884. [Google Scholar]
  10. Xu, Z.; Zhao, S.-J.; Liu, Y. 1, 2, 3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 2019, 183, 111700. [Google Scholar] [CrossRef]
  11. Saad, H.A.; Osman, N.A.; Moustafa, A.H. Synthesis and analgesic activity of some new pyrazoles and triazoles bearing a 6, 8-dibromo-2-methylquinazoline moiety. Molecules 2011, 16, 10187–10201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Reddy, M.K.; Kumar, K.S.; Sreenivas, P.; Krupadanam, G.D.; Reddy, K.J. Synthesis of novel 1, 4-disubstituted-1, 2, 3-triazole semi synthetic analogues of forskolin by click reaction. Tetrahedron Lett. 2011, 52, 6537–6540. [Google Scholar] [CrossRef]
  13. Aouad, M.R.; Almehmadi, M.A.; Rezki, N.; Al-blewi, F.F.; Messali, M.; Ali, I. Design, click synthesis, anticancer screening and docking studies of novel benzothiazole-1, 2, 3-triazoles appended with some bioactive benzofused heterocycles. J. Mol. Struct. 2019, 1188, 153–164. [Google Scholar] [CrossRef]
  14. Rezki, N.; Almehmadi, M.A.; Ihmaid, S.; Shehata, A.M.; Omar, A.M.; Ahmed, H.E.; Aouad, M.R. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1, 2, 3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. Bioorganic Chem. 2020, 103, 104133. [Google Scholar] [CrossRef] [PubMed]
  15. Almehmadi, M.A.; Aljuhani, A.; Alraqa, S.Y.; Ali, I.; Rezki, N.; Aouad, M.R.; Hagar, M. Design, synthesis, DNA binding, modeling, anticancer studies and DFT calculations of Schiff bases tethering benzothiazole-1, 2, 3-triazole conjugates. J. Mol. Struct. 2021, 1225, 129148. [Google Scholar] [CrossRef]
  16. Alraqa, S.Y.; Alharbi, K.; Aljuhani, A.; Rezki, N.; Aouad, M.R.; Ali, I. Design, click conventional and microwave syntheses, DNA binding, docking and anticancer studies of benzotriazole-1, 2, 3-triazole molecular hybrids with different pharmacophores. J. Mol. Struct. 2021, 1225, 129192. [Google Scholar] [CrossRef]
  17. Ihmaid, S.K.; Alraqa, S.Y.; Aouad, M.R.; Aljuhani, A.; Elbadawy, H.M.; Salama, S.A.; Rezki, N.; Ahmed, H.E. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability. Bioorganic Chem. 2021, 111, 104835. [Google Scholar] [CrossRef]
  18. Albelwi, F.F.; Teleb, M.; Abu-Serie, M.M.; Moaty, M.N.A.A.; Alsubaie, M.S.; Zakaria, M.A.; El Kilany, Y.; Aouad, M.R.; Hagar, M.; Rezki, N. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation. Int. J. Mol. Sci. 2021, 22, 10324. [Google Scholar] [CrossRef]
  19. Karakurt, A.; Aytemir, M.D.; Stables, J.P.; Özalp, M.; Betül Kaynak, F.; Özbey, S.; Dalkara, S. Synthesis of Some Oxime Ether Derivatives of 1-(2-Naphthyl)-2-(1, 2, 4-triazol-1-yl) ethanone and Their Anticonvulsant and Antimicrobial Activities. Arch. Der Pharm. 2006, 339, 513–520. [Google Scholar] [CrossRef]
  20. Kumudha, D.; Reddy, R.; Kalavathi, T. Synthesis and evaluation of some 1, 3, 4-thiadiazoles having substituted 1, 2, 4-triazole moiety for anticonvulsant and CNS depressant activity. World J. Pharm. Pharm. Sci. 2014, 3, 728–740. [Google Scholar]
  21. Kumar, S.; Sharma, B.; Mehra, V.; Kumar, V. Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1, 2, 3-triazoles. Eur. J. Med. Chem. 2021, 212, 113069. [Google Scholar] [CrossRef] [PubMed]
  22. Zhou, B.; He, Y.; Zhang, X.; Xu, J.; Luo, Y.; Wang, Y.; Franzblau, S.G.; Yang, Z.; Chan, R.J.; Liu, Y. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc. Natl. Acad. Sci. USA 2010, 107, 4573–4578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. El Sawy, M.A.; Elshatanofy, M.M.; El Kilany, Y.; Kandeel, K.; Elwakil, B.H.; Hagar, M.; Aouad, M.R.; Albelwi, F.F.; Rezki, N.; Jaremko, M. Novel Hybrid 1, 2, 4-and 1, 2, 3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking. Int. J. Mol. Sci. 2022, 23, 4706. [Google Scholar] [CrossRef]
  24. Massarotti, A.; Aprile, S.; Mercalli, V.; Del Grosso, E.; Grosa, G.; Sorba, G.; Tron, G.C. Are 1, 4- and 1, 5-Disubstituted 1, 2, 3-Triazoles Good Pharmacophoric Groups? ChemMedChem 2014, 9, 2497–2508. [Google Scholar] [CrossRef] [PubMed]
  25. Surineni, G.; Yogeeswari, P.; Sriram, D.; Kantevari, S. Rational design, synthesis and evaluation of novel-substituted 1, 2, 3-triazolylmethyl carbazoles as potent inhibitors of Mycobacterium tuberculosis. Med. Chem. Res. 2015, 24, 1298–1309. [Google Scholar] [CrossRef]
  26. Kamal, A.; Hussaini, S.M.A.; Faazil, S.; Poornachandra, Y.; Reddy, G.N.; Kumar, C.G.; Rajput, V.S.; Rani, C.; Sharma, R.; Khan, I.A.; et al. Anti-tubercular agents. Part 8: Synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1, 2, 3-triazoles. Bioorganic Med. Chem. Lett. 2013, 23, 6842–6846. [Google Scholar] [CrossRef]
  27. Patil, P.S.; Kasare, S.L.; Haval, N.B.; Khedkar, V.M.; Dixit, P.P.; Rekha, E.M.; Sriram, D.; Haval, K.P. Novel isoniazid embedded triazole derivatives: Synthesis, antitubercular and antimicrobial activity evaluation. Bioorganic Med. Chem. Lett. 2020, 30, 127434. [Google Scholar] [CrossRef]
  28. Shaikh, M.H.; Subhedar, D.D.; Nawale, L.; Sarkar, D.; Khan, F.A.K.; Sangshetti, J.N.; Shingate, B.B. 1, 2, 3-Triazole derivatives as antitubercular agents: Synthesis, biological evaluation and molecular docking study. MedChemComm 2015, 6, 1104–1116. [Google Scholar] [CrossRef]
  29. Aouad, M.R.; Khan, D.J.; Said, M.A.; Al-Kaff, N.S.; Rezki, N.; Ali, A.A.; Bouqellah, N.; Hagar, M. Novel 1, 2, 3-Triazole Derivatives as Potential Inhibitors against Covid-19 Main Protease: Synthesis, Characterization, Molecular Docking and DFT Studies. ChemistrySelect 2021, 6, 3468–3486. [Google Scholar] [CrossRef]
  30. Alzahrani, A.Y.; Shaaban, M.M.; Elwakil, B.H.; Hamed, M.T.; Rezki, N.; Aouad, M.R.; Zakaria, M.A.; Hagar, M. Anti-COVID-19 activity of some benzofused 1, 2, 3-triazolesulfonamide hybrids using in silico and in vitro analyses. Chemom. Intell. Lab. Syst. 2021, 217, 104421. [Google Scholar] [CrossRef]
  31. Said, M.A.; Khan, D.J.; Al-Blewi, F.F.; Al-Kaff, N.S.; Ali, A.A.; Rezki, N.; Aouad, M.R.; Hagar, M. New 1, 2, 3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects. Vaccines 2021, 9, 1012. [Google Scholar] [CrossRef] [PubMed]
  32. Kamsri, P.; Hanwarinroj, C.; Phusi, N.; Pornprom, T.; Chayajarus, K.; Punkvang, A.; Suttipanta, N.; Srimanote, P.; Suttisintong, K.; Songsiriritthigul, C.; et al. Discovery of new and potent InhA inhibitors as antituberculosis agents: Structure-based virtual screening validated by biological assays and X-ray crystallography. J. Chem. Inf. Modeling 2019, 60, 226–234. [Google Scholar] [CrossRef] [PubMed]
  33. Phatak, P.S.; Bakale, R.D.; Kulkarni, R.S.; Dhumal, S.T.; Dixit, P.P.; Krishna, V.S.; Sriram, D.; Khedkar, V.M.; Haval, K.P. Design and synthesis of new indanol-1, 2, 3-triazole derivatives as potent antitubercular and antimicrobial agents. Bioorganic Med. Chem. Lett. 2020, 30, 127579. [Google Scholar] [CrossRef] [PubMed]
  34. Kaushik, C.; Pahwa, A.; Singh, D.; Kumar, K.; Luxmi, R. Efficient synthesis, antitubercular and antimicrobial evaluation of 1, 4-disubstituted 1, 2, 3-triazoles with amide functionality. Mon. Für Chem.-Chem. Mon. 2019, 150, 1127–1136. [Google Scholar] [CrossRef]
  35. Rozwarski, D.A.; Vilcheze, C.; Sugantino, M.; Bittman, R.; Sacchettini, J.C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 1999, 274, 15582–15589. [Google Scholar] [CrossRef] [Green Version]
  36. Naik, S.K.; Mohanty, S.; Padhi, A.; Pati, R.; Sonawane, A. Evaluation of antibacterial and cytotoxic activity of Artemisia nilagirica and Murraya koenigii leaf extracts against mycobacteria and macrophages. Altern. Med. 2014, 14, 87. [Google Scholar] [CrossRef]
  37. Devender, N.; Gunjan, S.; Tripathi, R.; Tripathi, R.P. Synthesis and antiplasmodial activity of novel indoleamide derivatives bearing sulfonamide and triazole pharmacophores. Eur. J. Med. Chem. 2017, 131, 171–184. [Google Scholar] [CrossRef]
  38. Wang, G.; Peng, Z.; Wang, J.; Li, X.; Li, J. Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential α-glucosidase inhibitors. Eur. J. Med. Chem. 2017, 125, 423–429. [Google Scholar] [CrossRef]
  39. Minvielle, M.J.; Bunders, C.A.; Melander, C. Indole–triazole conjugates are selective inhibitors and inducers of bacterial biofilms. MedChemComm 2013, 4, 916–919. [Google Scholar] [CrossRef]
  40. Rezki, Z.; Aouad, M.R. Green ultrasound-assisted three-component click synthesis of novel 1H-1, 2, 3-triazole carrying benzothiazoles and fluorinated-1, 2, 4-triazole conjugates and their antimicrobial evaluation. Acta Pharm. 2017, 67, 309–324. [Google Scholar] [CrossRef] [Green Version]
  41. Rodriguez, F.; Saffon, N.; Sammartino, J.C.; Degiacomi, G.; Pasca, M.R.; Lherbet, C. First triclosan-based macrocyclic inhibitors of InhA enzyme. Bioorganic Chem. 2020, 95, 103498. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 15 00799 g001 550
Figure 1. Drugs with the 1,2,3-triazole unit on the market.
Figure 1. Drugs with the 1,2,3-triazole unit on the market.
Pharmaceuticals 15 00799 g001
Pharmaceuticals 15 00799 g002 550
Figure 2. Representative examples of 1,2,3-triazole derivatives having antitubercular activity.
Figure 2. Representative examples of 1,2,3-triazole derivatives having antitubercular activity.
Pharmaceuticals 15 00799 g002
Pharmaceuticals 15 00799 g003 550
Figure 3. Ligand-based design of target structure.
Figure 3. Ligand-based design of target structure.
Pharmaceuticals 15 00799 g003
Pharmaceuticals 15 00799 sch001 550
Scheme 1. Click synthesis of 1,2,3-triazole-acetophenone conjugates 9–14.
Scheme 1. Click synthesis of 1,2,3-triazole-acetophenone conjugates 9–14.
Pharmaceuticals 15 00799 sch001
Pharmaceuticals 15 00799 g004 550
Figure 4. The inhibition percentage at 10 µM.
Figure 4. The inhibition percentage at 10 µM.
Pharmaceuticals 15 00799 g004
Pharmaceuticals 15 00799 g005 550
Figure 5. (A): Docking and binding pattern of compound 9 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 9 (brown) with the co-crystallized ligand (purple) into inhA active site in 2D (right panel) and 3D (left panel).
Figure 5. (A): Docking and binding pattern of compound 9 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 9 (brown) with the co-crystallized ligand (purple) into inhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g005
Pharmaceuticals 15 00799 g006 550
Figure 6. (A): Docking and binding pattern of compound 10 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 10 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Figure 6. (A): Docking and binding pattern of compound 10 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 10 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g006
Pharmaceuticals 15 00799 g007 550
Figure 7. (A) Docking and binding pattern of compound 14 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 14 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Figure 7. (A) Docking and binding pattern of compound 14 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 14 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g007
Pharmaceuticals 15 00799 g008 550
Figure 8. (A): Docking and binding pattern of compound 11 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 11 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Figure 8. (A): Docking and binding pattern of compound 11 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 11 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g008
Pharmaceuticals 15 00799 g009 550
Figure 9. (A): Docking and binding pattern of compound 12 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 12 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Figure 9. (A): Docking and binding pattern of compound 12 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 12 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g009
Pharmaceuticals 15 00799 g010 550
Figure 10. (A): Docking and binding pattern of compound 13 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 13 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Figure 10. (A): Docking and binding pattern of compound 13 into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel). (B): An overlay of the docked pose of compound 13 (brown) with the co-crystallized ligand (purple) into InhA active site in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g010
Pharmaceuticals 15 00799 g011 550
Figure 11. Docking and binding pattern of compound Lead structure B into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel).
Figure 11. Docking and binding pattern of compound Lead structure B into InhA active site (PDB ID: 4UVD) in 2D (right panel) and 3D (left panel).
Pharmaceuticals 15 00799 g011
Table
Table 1. InhA inhibition (IC50) of 9-14 with respect to rifampicin.
Table 1. InhA inhibition (IC50) of 9-14 with respect to rifampicin.
CodeStructureIC50 (µM)
Rifampicin Pharmaceuticals 15 00799 i0018.50
Isoniazide Pharmaceuticals 15 00799 i0020.054
9 Pharmaceuticals 15 00799 i0030.005
10 Pharmaceuticals 15 00799 i0040.008
11 Pharmaceuticals 15 00799 i0050.043
12 Pharmaceuticals 15 00799 i0060.041
13 Pharmaceuticals 15 00799 i0070.084
14 Pharmaceuticals 15 00799 i0080.002
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Albelwi, F.F.; Abdu Mansour, H.M.; Elshatanofy, M.M.; El Kilany, Y.; Kandeel, K.; Elwakil, B.H.; Hagar, M.; Aouad, M.R.; El Ashry, E.S.H.; Rezki, N.; et al. Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors. Pharmaceuticals 2022, 15, 799. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15070799

AMA Style

Albelwi FF, Abdu Mansour HM, Elshatanofy MM, El Kilany Y, Kandeel K, Elwakil BH, Hagar M, Aouad MR, El Ashry ESH, Rezki N, et al. Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors. Pharmaceuticals. 2022; 15(7):799. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15070799

Chicago/Turabian Style

Albelwi, Fawzia Faleh, Hanaa M. Abdu Mansour, Maram M. Elshatanofy, Yeldez El Kilany, Kamal Kandeel, Bassma H. Elwakil, Mohamed Hagar, Mohamed Reda Aouad, El Sayed H. El Ashry, Nadjet Rezki, and et al. 2022. "Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors" Pharmaceuticals 15, no. 7: 799. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15070799

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop